FDA to re-review application for AstraZeneca’s hyperkalaemia treatment
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Hyperkalaemia (potassium levels > 5.0 mEq/L in the blood serum) occurs in patients with advanced chronic kidney disease and chronic heart failure...